Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-803-0 | CAS number: 88-14-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity:oral:
Groups of 12 male and 12 female rats were fed 0, 0.1, 0.5, 0.8 or 1.2% fumaric acid, and groups of 12 male rats were fed 0, 0.5, 1 or 1.5% fumaric acid for 2 years.A very slight increase in mortality rate and some testicular atrophy was observed after administration of 1.5% fumaric acid (approximately 750 mg/kg bw/day). Gross and microscopic examination of major organs revealed no abnormalities. Two rats receiving 1% or 0.5% had stomach inflammation. The authors of this study concluded that inanition was partly responsible for testicular atrophy. In the study with female rats, no adverse effects on reproductive organs were observed after administration of up to 1.2% fumaric acid in the diet. Based on the low incidence of mortality of male rats, 1.2% is very near a NOAEL for chronic exposure to fumaric acid (600 mg/kg bw). The 1.2% NOAEL (600 mg/kg bw/day) derived from the available long term rat toxicity data was confirmed as the appropriate point of departure by two reviews - The International Programme on Chemical Safety (WHO 1975 Food Additive Series 6) report and the findings of the European Commission DG C Report of the Scientific Committee on animal nutrition on the safety of fumaric acid.
Repeated dose toxicity: inhalation:
The acute inhalation toxicity study need not be conducted because exposure to humans via inhalation route is not likely taking into account due to the low vapour pressure of the test chemical, which is reported to be 13.73 Pa. = 0.103 mmHg.Thus, exposure to inhalable dust, mist and vapour of the chemical is highly unlikely. Therefore this study is considered for waiver.
Repeated dose toxicity: Dermal:
The acute dermal toxicity value for test chemical (as provided in section 7.2.3) is >2000 mg/kg body weight. Given the use of the chemical; repeated exposure by the dermal route is unlikely since the use of gloves is common practice in industries. Thus, it is expected that test chemical shall not exhibit 28 day repeated dose toxicity by the dermal route. In addition, there is no data available that suggests that test chemical shall exhibit repeated dose toxicity by the dermal route. Hence this end point was considered for waiver.
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- significant methodological deficiencies
- Justification for type of information:
- Data for the target chemical is summarized based on the structurally similar read across chemicals
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- other: As mentioned below
- Principles of method if other than guideline:
- The study was a chronic exposure feeding study (conducted prior to development of the guidelines), limited to the evaluation of body weight, food consumption and histopathology of the main organs.
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- other: 2.Osborne-Mendel 3.Fischer 344/DuCrj
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- 2. The animals were male and female weanling rats (21-days) of the Osborn-Mendel strain. All animals were kept in individual cages in a room with temperature and humidity controlled for the duration of the experiment. Animals were given free access to their respective diets and water.
3.Animals: Five-week-old SPF male and female F344/DuCrj rats (Charles River Laboratories Japan,
Inc.) were fed and acclimated for 1 week and then divided into 2 groups. Feeding conditions: White
flakes were used as bedding in a plastic cage. The animals were fed in a animal feeding room of a
semi-barrier system - Route of administration:
- other: 2. oral: feed 3.both feed and water
- Details on route of administration:
- Not specified
- Vehicle:
- other: 2. cod liver oil added to moisten diet 3. Not specified
- Details on oral exposure:
- 2. Weanling rats (21 days) were fed diets containing fumaric acid for two years. The basic diet consisted of ground commercial rat biscuits with 1% added cod-liver oil. Fumaric acid was mixed with the basic diet using a rotary batch mixer.
3.Experiment I
Calcium lactate was dissolved in ion-exchanged water at concentrations of 5, 2.5, 1.25, 0.6, and
0.3% since it was water-soluble and stable. Each experimental group was given ad libitum one of
these solutions as the drinking water for 13 weeks. The control group was similarly given only ionexchanged water. Each group was given ad libitum elemental diet (CRF-1 manufactured by Orien
tal Yeast Co., Ltd.). The highest dose was set based on the fact that the maximum solubility of this
product in water was 5%. Each 5 male and female rats from each group were used, and all the survi
ving animals were sacrificed for autopsy in the 13th week.
Experiment II
Ten male and ten female were used. Calcium lactate was mixed at 30, 20, 10, 5, and 0% in the stan
dard blend of purified diet [B-blend powder diet (Oriental Yeast Co., Ltd.)] and given ad libitum to the
animals for 20 weeks. Each 5 male and female rats from each group were autopsied in the 8th week
after the start of the experiment, and the remaining rats were sacrificed for autopsy in the 20th week.
Experiment III
Twenty male rats were divided into 2 groups. One group was given the B-blend powder diet, while the
other group was given at libitum the CRF-1 solid diet. The rats in both groups were given ad libitum
ion-exchanged water as the drinking water. Five rats from each group were sacrificed in the 4th week
after the start of the experiment and the remaining rats were sacrificed for autopsy in the 8th week. - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- No data
- Duration of treatment / exposure:
- 2. 2 years
3. 13 weeks - Frequency of treatment:
- 2. Ad libitum in feed
3.13 weeks - Remarks:
- Experiment I(0, 0.1, 0.5, 0.8 and 1.2% nominal in diet)/2
- Remarks:
- Experiment II(0, 0.5, 1.0, and 1.5% nominal in diet)/2
- Remarks:
- Experiment I (0, 0.3, 0.6, 1.25, 2.5, 5% in water) /3
- Remarks:
- Experiment II (0, 5, 10, 20, 30 % in food)/3.
- No. of animals per sex per dose:
- 2. Experiment 1 (0, 0.1, 0.5, 0.8 and 1.2%): 12 males and 12 females per group.
Experiment 2 (0, 0.5, 1.0 and 1.5%): 12 males
3.10 - Control animals:
- yes, plain diet
- Details on study design:
- 2. Two experiments were conducted concurrently, employing two different dosing regimens. The first experiment included both male and female rats, exposed to 0, 0.1, 0.5, 0.8 and 1.2% fumaric acid in the diet. The second experiment was conducted in order to compare the toxicities of fumaric and maleic acids more closely; male rats were fed diets containing 0, 0.5, 1.0 and 1.5% fumaric or maleic acid.
3. - Positive control:
- 2.None
- Observations and examinations performed and frequency:
- 2.Individual animal weights and food consumption were determined at weekly intervals.
3.CAGE SIDE OBSERVATIONS: Minimal
BODY WEIGHT: Yes
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g
food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted
averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
HAEMATOLOGY: Yes
- Time schedule for collection of blood: 8 wks / end of study
CLINICAL CHEMISTRY: Yes
URINALYSIS: Yes - Sacrifice and pathology:
- 2. Gross pathology and histopathology of lung, heart, liver, spleen, pancrease, stomach, small intestine, kidney, adrenal and testis.
Additional structures examined by histopathology include colon, bone marrow, leg bones, leg muscles, lymph nodes, uterus, ovary, thyroid and parathyroid.
3.GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: No data - Other examinations:
- None
- Statistics:
- No details
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- 2. Mortality in the high dose group was significant but low mortality rates evident in lower dose groups (detailed information not provided in study report)
3. No data - Mortality:
- mortality observed, treatment-related
- Description (incidence):
- 2.Mortality in the high dose group was significant but low mortality rates evident in lower dose groups
3. No data - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- 2.weight gains recorded for males and females at each dose level showed no treatment related effects (data were presented for 1 year only3. No data
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- 2.Food consumption over the first 26 weeks of the study and second 26 weeks were compared for each treatment group. No statistically significant changes observed (no detailed information is included in the study report).
3. No data - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- 2.Sporadic findings reported but no treatment relationship established
3. No data - Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Details on results:
- 2. At two years, there were only 2 animals living on 1.5% fumaric acid.; other dose levels had no effect on mortality rate. Animals fed 1.5% fumaric acid showed more atrophy of the testis and 2 rats fed 0.5% and 1.0% fumaric acid showed phlegmonous gastritis.
3. All observed effects could be attributed to calcium overload/imbalance. No lactate toxicity was
observed. - Dose descriptor:
- NOEL
- Remarks:
- 2.
- Effect level:
- ca. 600 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Low incidence of mortality seen at a dose level of 1.5%
- Dose descriptor:
- NOAEL
- Remarks:
- 3.
- Effect level:
- 50 000 mg/L drinking water
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- not specified
- Conclusions:
- A NOAEL of (600 mg/kg bw/day) was observed in a 2 year study in Groups of 12 male and 12 female rats.
- Executive summary:
Data available for the test chemical and read across chemicals was reviewed to determine the repeated dose oral toxic nature of test chemical. The study is as mentioned below:
1)Groups of 12 male and 12 female rats were fed 0, 0.1, 0.5, 0.8 or 1.2% fumaric acid, and groups of 12 male rats were fed 0, 0.5, 1 or 1.5% fumaric acid for 2 years.A very slight increase in mortality rate and some testicular atrophy was observed after administration of 1.5% fumaric acid (approximately 750 mg/kg bw/day). Gross and microscopic examination of major organs revealed no abnormalities. Two rats receiving 1% or 0.5% had stomach inflammation. The authors of this study concluded that inanition was partly responsible for testicular atrophy. In the study with female rats, no adverse effects on reproductive organs were observed after administration of up to 1.2% fumaric acid in the diet. Based on the low incidence of mortality of male rats, 1.2% is very near a NOAEL for chronic exposure to fumaric acid (600 mg/kg bw). The 1.2% NOAEL (600 mg/kg bw/day) derived from the available long term rat toxicity data was confirmed as the appropriate point of departure by two reviews - The International Programme on Chemical Safety (WHO 1975 Food Additive Series 6) report and the findings of the European Commission DG C Report of the Scientific Committee on animal nutrition on the safety of fumaric acid.
2)In a subchronic toxicity study (similar to OECD 408), Calcium lactate was administered to Fischer 344/DuCrj rats. In Experiment I, Calcium lactate was mixed at 5, 2.5, 1.25, 0.6, and 0.3 % in the drinking water and the rats were given this solution ad libitum for 13 weeks. As a result, the inhibition of body weight gain in the 5% group fell within 10% of that in the control group. Some examination values showed variations in the hematological and hematobiochemical studies, but no controversial findings were obtained in the pathohistological search. Since the highest solubility of Calcium lactate is 5%, experiments II and III were carried out by giving blended diet in order to study the toxicity at higher doses. In experiment II, Calcium lactate was mixed at concentrations of 30, 20, 10, and 5% in the B-blend powder diet and then the rats were given this diet ad libitum for 20 weeks. In experiment III, the rats were given the CRF-1 or the B-blend powder diet ad libitum for 8 weeks. As a result, in experiment II, nephrocalcinosis was observed in all the groups including the control group. The degree of the lesion was in reverse correlation with the administered concentrations of calcium and the lesion was seen more intensely in female rats. In experiment III, nephrocalcinosis resulting from the administration of the B-blend diet was already observed in the 4th week. Nephrocalcinosis as observed in experiments II and III was attributable to the small Ca/P value in the B-blend diet.
From the above results, the optimal dose for a long-term toxicity/carcinogenicity study has been determined to be 5 and 2.5% based on the values obtained from experiment I.
Based on the data available for the target chemical and read across chemical, test chemical is not likely to classify as a toxicant upon repeated exposure by oral route.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 600 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Data is from K2 peer reviewed publication
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- Waiver
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- Waiver
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose toxicity: Oral
Data available for the test chemical and read across chemicals was reviewed to determine the repeated dose oral toxic nature of test chemical. The study is as mentioned below:
1)Groups of 12 male and 12 female rats were fed 0, 0.1, 0.5, 0.8 or 1.2% fumaric acid, and groups of 12 male rats were fed 0, 0.5, 1 or 1.5% fumaric acid for 2 years.A very slight increase in mortality rate and some testicular atrophy was observed after administration of 1.5% fumaric acid (approximately 750 mg/kg bw/day). Gross and microscopic examination of major organs revealed no abnormalities. Two rats receiving 1% or 0.5% had stomach inflammation. The authors of this study concluded that inanition was partly responsible for testicular atrophy. In the study with female rats, no adverse effects on reproductive organs were observed after administration of up to 1.2% fumaric acid in the diet. Based on the low incidence of mortality of male rats, 1.2% is very near a NOAEL for chronic exposure to fumaric acid (600 mg/kg bw). The 1.2% NOAEL (600 mg/kg bw/day) derived from the available long term rat toxicity data was confirmed as the appropriate point of departure by two reviews - The International Programme on Chemical Safety (WHO 1975 Food Additive Series 6) report and the findings of the European Commission DG C Report of the Scientific Committee on animal nutrition on the safety of fumaric acid.
2)In a subchronic toxicity study (similar to OECD 408), Calcium lactate was administered to Fischer 344/DuCrj rats. In Experiment I, Calcium lactate was mixed at 5, 2.5, 1.25, 0.6, and 0.3 % in the drinking water and the rats were given this solution ad libitum for 13 weeks. As a result, the inhibition of body weight gain in the 5% group fell within 10% of that in the control group. Some examination values showed variations in the hematological and hematobiochemical studies, but no controversial findings were obtained in the pathohistological search. Since the highest solubility of Calcium lactate is 5%, experiments II and III were carried out by giving blended diet in order to study the toxicity at higher doses. In experiment II, Calcium lactate was mixed at concentrations of 30, 20, 10, and 5% in the B-blend powder diet and then the rats were given this diet ad libitum for 20 weeks. In experiment III, the rats were given the CRF-1 or the B-blend powder diet ad libitum for 8 weeks. As a result, in experiment II, nephrocalcinosis was observed in all the groups including the control group. The degree of the lesion was in reverse correlation with the administered concentrations of calcium and the lesion was seen more intensely in female rats. In experiment III, nephrocalcinosis resulting from the administration of the B-blend diet was already observed in the 4th week. Nephrocalcinosis as observed in experiments II and III was attributable to the small Ca/P value in the B-blend diet.
From the above results, the optimal dose for a long-term toxicity/carcinogenicity study has been determined to be 5 and 2.5% based on the values obtained from experiment I.
Subacute repeated oral toxicity study was performed to determine the oral toxic nature of test chemical upon repeated exposure for 14 days. The study was performed using male Sprague Dawley rats. The test chemical was dissolved in 1% CMC and used at dose levels of 0 or 20 mg/Kg/day.On day 7 and 14, the animals were bled between 7:30-8:30 a.m. Serum Cholesterol and triglycerides were determined. The animals were sacrificed on day 14. Test chemical at 20 mg/kg/day orally suppressed the serum cholesterol levels 50% and serum triglyceride levels 42% after 14 days in rats. The HDL cholesterol content was elevated 34% on day 14. The VLDL and LDL cholesterol levels were not reduced at this dose. Based on the data available, the No Observed adverse effect level (NOAEL) for test chemical is considered to be 20 mg/Kg bw.
Based on the data available for the target chemical and read across chemical, test chemical is not likely to classify as a toxicant upon repeated exposure by oral route.
Repeated dose toxicity: inhalation:
The acute inhalation toxicity study need not be conducted because exposure to humans via inhalation route is not likely taking into account due to the low vapour pressure of the test chemical, which is reported to be 13.73 Pa. = 0.103 mmHg.Thus, exposure to inhalable dust, mist and vapour of the chemical is highly unlikely. Therefore this study is considered for waiver.
Repeated dose toxicity: Dermal:
The acute dermal toxicity value for test chemical (as provided in section 7.2.3) is >2000 mg/kg body weight. Given the use of the chemical; repeated exposure by the dermal route is unlikely since the use of gloves is common practice in industries. Thus, it is expected that test chemical shall not exhibit 28 day repeated dose toxicity by the dermal route. In addition, there is no data available that suggests that test chemical shall exhibit repeated dose toxicity by the dermal route. Hence this end point was considered for waiver.
Justification for classification or non-classification
Based on the data available for the target chemical,test chemical is not likely to classify as a toxicant upon repeated exposure by oral route. For repeated inhalation and repeated dermal toxicity wavier was added so, not possible to classify.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
